H osts and viruses are under a constant coevolution pressure. Schematically, a virus (as a population) requires a permanent supply of naive hosts to continue to exist, and survival of the host population relies on its ability to develop antiviral defenses. Severe acute respiratory syndrome coronavirus, Henipaviruses (Hendra and Nipah) and filoviruses (Ebola and Marburg) are apt examples. On the one hand, they benignly colonize bats to survive, and on the other hand, thanks to the use of highly conserved cellular receptors (1), they are deadly pathogens for several other mammals, including humans, in which they induce selfextinguishing local epidemics. The virus and host coevolution can narrow down to a virus reservoir limited to a single animal species as illustrated by measles virus (MeV), a human-only pathogen. In the absence of an animal reservoir, the survival of MeV relies on its access to human populations large enough to allow an unbroken chain of acute infections (2). Measles, a major childhood killer disease of the prevaccination era, is attributable to an acute infection by one of the most highly contagious human pathogens. Virus transmission is limited because of the short time window during which infected individuals are contagious and because of the lifelong sterilizing immunity that MeV induces. Since the identification of CD46/membrane cofactor protein (MCP) (1993) and CD150/signalling lymphocyteactivation molecule (SLAM) (2000) as receptors mediating MeV entry into human cells, several transgenic mouse models of measles disease have been developed. However, these poorly reproduce the human disease, with viral dissemination observed only in mouse neonates. The mouse interferon (IFN) system appears to be a major host-restriction parameter because only human receptor transgenic mice with a disabled IFN system show susceptibility to MeV infection (3). However, in PNAS, Iwasaki and Yanagi (4) present an original strategy to overcome IFN-mediated restriction in mouse cells.
Human viral diseases result from a highly complex interplay between viruses and their hosts. Clinical studies have been very useful in defining major pathways of virus pathogenicity, and in vitro studies are providing a growing and complex set of molecular and cellular clues as to how they have effect. To integrate both types of findings, there is a strong need for new animal models that are more reliable mimics of the human diseases. Expanding ethical concerns render such in vivo models indispensable for obtaining a detailed and dynamic understanding of viral dissemination, analyzing the host responses at specific tissue and whole-organism levels, and permitting the testing of novel vaccines and antivirals. However, the development of relevant animal models is a daunting task. A major problem is that most viruses exhibit a very limited host range, the consequence of a continuous coevolution process between a virus and its host species. The relations between the poxviruses and the primates are a good illustration of the never-ending process of reciprocal adaptation. The primate PKR gene, one of the key members of the cell's intrinsic innate immune system, and the viral K3L gene, a lure substrate for PKR, are among the fastest evolving genes in the poxvirus/primate pairwise coevolution (5) . At the forefront of this coevolution, the cell's intrinsic innate immunity is the earliest line of the host's active defense. Consequently, any genetic defect in the innate immunity machinery usually results in a much higher susceptibility to viral infections (6) . Type I and type III IFNs are the central cytokines responsible for inducing the antiviral state in infected cells. On binding to their cognate receptors, they activate STAT1 and STAT2 transcription factors that govern the expression of hundreds of cellular genes endowed with antiviral activities.
Iwasaki and Yanagi (4) have used the C protein from Sendai virus (SeV) to block the mouse IFN signaling pathway to facilitate the infection of mouse cells by the human pathogen MeV. SeV, another paramyxovirus that has a similar genomic organization to MeV, is a natural mouse pathogen. MeV-V protein binds to the human STAT1/STAT2 complex (7-9) but not to the mouse STAT1/STAT2 complex (4) and, consequently, can only inhibit IFN signaling in human cells. SeV-C protein, however, an obligate virulence factor in mice (10), inhibits both human and mouse IFN signaling pathways by efficiently targeting the STAT1/STAT2 complex from both species (4, 11, 12) . Transient expression of SeV-C protein was found to increase MeV replication strongly in mouse cells expressing human CD150/SLAM by dampening mouse IFN signaling. To mimic the infection process more closely, Iwasaki and Yanagi (4) have designed an elegant system that allows the selective expression of SeV-C protein on infection by MeV. Because of biological safety concerns, they rationally chose not to build a recombinant MeV encoding the SeV-C protein because this could potentially exhibit higher pathogenicity in humans. Instead, they used the Cre/loxP system to express the SeV-C protein conditionally in mouse cells on infection by a MeV engineered to code for the Cre recombinase from the P1 phage. A CD150/SLAM mouse cell line was generated with the SeV-C gene interrupted by a "floxed" gene used to select the cell line positively in the presence of an antibiotic. The floxed selection gene is flanked by two loxP nucleotide sequences from P1 phage (Fig. 1) so that in the absence of Cre recombinase, mouse cells express only the upstream selection gene and not SeV-C. On infection by a MeV-Cre recombinant virus, the virally encoded Cre recognizes the two loxP sequences integrated into the mouse genome and uses them to cleave off the selection gene. As a consequence, the infected cells can now express the SeV-C protein.
Mimicking what occurs during MeV infection of a human cell monolayer, MeV-Cre then spreads from cell to cell throughout the mouse cell monolayer by "switching on" the blockade of IFN signaling by SeV-C protein as each cell becomes infected (Fig. 1 ). Iwasaki and Yanagi (4) thus establish the proof of concept of successful MeV propagation in mouse cell culture by means of the use of a Trojan MeV-Cre virus to activate a dormant SeV-C protein, which then acts as an insurgent against the mouse IFN-mediated defenses. The development of a mouse transgenic model for both CD150/SLAM and a Cre-dependent SeV-C gene will be the next step to determine to what extent this strategy can be translated into a useful mouse model of measles infection.
On the basis of our available knowledge, some hurdles can be foreseen that may
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delay the establishment of a mouse MeV infection model faithfully mimicking the human disease. The complex pattern of the anti-innate immunity activity of SeV-C proteins in mouse cells is likely to be divergent from that exerted by MeV-V, MeV-C, and MeV-P proteins in human cells (6, 13, 14 The system developed by Iwasaki and Yanagi (4) will likely boost many research fields by opening new doors. It is a platform toward the building of new mouse models for MeV infection. For example, a coupling with the genetic engineering of mouse epithelium to express the more efficient human poliovirus receptor-like 4 (19) may allow deciphering of the contribution of epithelium infection in virus shedding in the airways and transmission of the disease (20) . The use of other viral proteins targeting different arms of the mouse innate immune system will allow the identification of those that MeV needs to counteract. Finally, this strategy can be transposed to build better models for other human viral diseases.
